Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Yeast-produced subunit protein vaccine elicits broadly neutralizing antibodies that protect mice against Zika virus lethal infection.

Zhang W, Qu P, Li D, Zhang C, Liu Q, Zou G, Dupont-Rouzeyrol M, Lavillette D, Jin X, Yin F, Huang Z.

Antiviral Res. 2019 Aug 5;170:104578. doi: 10.1016/j.antiviral.2019.104578. [Epub ahead of print]

2.

Comparative study of chikungunya Virus-Like Particles and Pseudotyped-Particles used for serological detection of specific immunoglobulin M.

Theillet G, Martinez J, Steinbrugger C, Lavillette D, Coutard B, Papageorgiou N, Dalbon P, Leparc-Goffart I, Bedin F.

Virology. 2019 Mar;529:195-204. doi: 10.1016/j.virol.2019.01.027. Epub 2019 Jan 30.

PMID:
30721816
3.

Negligible contribution of M2634V substitution to ZIKV pathogenesis in AG6 mice revealed by a bacterial promoter activity reduced infectious clone.

Zhao F, Xu Y, Lavillette D, Zhong J, Zou G, Long G.

Sci Rep. 2018 Jul 12;8(1):10491. doi: 10.1038/s41598-018-28890-0.

4.

Role of Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.

Tong Y, Lavillette D, Li Q, Zhong J.

Front Immunol. 2018 Jun 19;9:1411. doi: 10.3389/fimmu.2018.01411. eCollection 2018. Review.

5.

Correction: Histone demethylase LSD1 restricts influenza A virus infection by erasing IFITM3-K88 monomethylation.

Shan J, Zhao B, Shan Z, Nie J, Deng R, Xiong R, Tsun A, Pan W, Zhao H, Chen L, Jin Y, Qian Z, Lui K, Liang R, Li D, Sun B, Lavillette D, Xu K, Li B.

PLoS Pathog. 2018 Apr 30;14(4):e1007037. doi: 10.1371/journal.ppat.1007037. eCollection 2018 Apr.

6.

A protein coevolution method uncovers critical features of the Hepatitis C Virus fusion mechanism.

Douam F, Fusil F, Enguehard M, Dib L, Nadalin F, Schwaller L, Hrebikova G, Mancip J, Mailly L, Montserret R, Ding Q, Maisse C, Carlot E, Xu K, Verhoeyen E, Baumert TF, Ploss A, Carbone A, Cosset FL, Lavillette D.

PLoS Pathog. 2018 Mar 5;14(3):e1006908. doi: 10.1371/journal.ppat.1006908. eCollection 2018 Mar.

7.

Histone demethylase LSD1 restricts influenza A virus infection by erasing IFITM3-K88 monomethylation.

Shan J, Zhao B, Shan Z, Nie J, Deng R, Xiong R, Tsun A, Pan W, Zhao H, Chen L, Jin Y, Qian Z, Lui K, Liang R, Li D, Sun B, Lavillette D, Xu K, Li B.

PLoS Pathog. 2017 Dec 27;13(12):e1006773. doi: 10.1371/journal.ppat.1006773. eCollection 2017 Dec. Erratum in: PLoS Pathog. 2018 Apr 30;14 (4):e1007037.

8.

Co-Infection of Mosquitoes with Chikungunya and Dengue Viruses Reveals Modulation of the Replication of Both Viruses in Midguts and Salivary Glands of Aedes aegypti Mosquitoes.

Le Coupanec A, Tchankouo-Nguetcheu S, Roux P, Khun H, Huerre M, Morales-Vargas R, Enguehard M, Lavillette D, Missé D, Choumet V.

Int J Mol Sci. 2017 Aug 4;18(8). pii: E1708. doi: 10.3390/ijms18081708.

9.

Specialization of Hepatitis C Virus Envelope Glycoproteins for B Lymphocytes in Chronically Infected Patients.

Douam F, Bobay LM, Maurin G, Fresquet J, Calland N, Maisse C, Durand T, Cosset FL, Féray C, Lavillette D.

J Virol. 2015 Nov 4;90(2):992-1008. doi: 10.1128/JVI.02516-15. Print 2016 Jan 15.

10.

Determinants Involved in Hepatitis C Virus and GB Virus B Primate Host Restriction.

Marnata C, Saulnier A, Mompelat D, Krey T, Cohen L, Boukadida C, Warter L, Fresquet J, Vasiliauskaite I, Escriou N, Cosset FL, Rey FA, Lanford RE, Karayiannis P, Rose NJ, Lavillette D, Martin A.

J Virol. 2015 Dec;89(23):12131-44. doi: 10.1128/JVI.01161-15. Epub 2015 Sep 23.

11.

A Lentiviral Vector Allowing Physiologically Regulated Membrane-anchored and Secreted Antibody Expression Depending on B-cell Maturation Status.

Fusil F, Calattini S, Amirache F, Mancip J, Costa C, Robbins JB, Douam F, Lavillette D, Law M, Defrance T, Verhoeyen E, Cosset FL.

Mol Ther. 2015 Nov;23(11):1734-1747. doi: 10.1038/mt.2015.148. Epub 2015 Aug 18.

12.

Functional and Biochemical Characterization of Hepatitis C Virus (HCV) Particles Produced in a Humanized Liver Mouse Model.

Calattini S, Fusil F, Mancip J, Dao Thi VL, Granier C, Gadot N, Scoazec JY, Zeisel MB, Baumert TF, Lavillette D, Dreux M, Cosset FL.

J Biol Chem. 2015 Sep 18;290(38):23173-87. doi: 10.1074/jbc.M115.662999. Epub 2015 Jul 29.

13.

Low cross-neutralization of hepatitis C correlates with liver disease in immunocompromized patients.

Maurin G, Halgand B, Bruscella P, Fresquet J, Duclos-Vallée JC, Roque-Afonso AM, Cosset FL, Samuel D, Lavillette D, Féray C.

AIDS. 2015 Jun 1;29(9):1025-33. doi: 10.1097/QAD.0000000000000651.

PMID:
26125137
14.

New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A.

Fénéant L, Potel J, François C, Sané F, Douam F, Belouzard S, Calland N, Vausselin T, Rouillé Y, Descamps V, Baumert TF, Duverlie G, Lavillette D, Hober D, Dubuisson J, Wychowski C, Cocquerel L.

J Virol. 2015 Aug;89(16):8346-64. doi: 10.1128/JVI.00192-15. Epub 2015 Jun 3.

15.

The mechanism of HCV entry into host cells.

Douam F, Lavillette D, Cosset FL.

Prog Mol Biol Transl Sci. 2015;129:63-107. doi: 10.1016/bs.pmbts.2014.10.003. Epub 2014 Dec 12. Review.

PMID:
25595801
16.

The sheep tetherin paralog oBST2B blocks envelope glycoprotein incorporation into nascent retroviral virions.

Murphy L, Varela M, Desloire S, Ftaich N, Murgia C, Golder M, Neil S, Spencer TE, Wootton SK, Lavillette D, Terzian C, Palmarini M, Arnaud F.

J Virol. 2015 Jan;89(1):535-44. doi: 10.1128/JVI.02751-14. Epub 2014 Oct 22.

17.

Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs.

Girard-Gagnepain A, Amirache F, Costa C, Lévy C, Frecha C, Fusil F, Nègre D, Lavillette D, Cosset FL, Verhoeyen E.

Blood. 2014 Aug 21;124(8):1221-31. doi: 10.1182/blood-2014-02-558163. Epub 2014 Jun 20.

18.

The expression of the hepatocyte SLAMF3 (CD229) receptor enhances the hepatitis C virus infection.

Cartier F, Marcq I, Douam F, Ossart C, Regnier A, Debuysscher V, Lavillette D, Bouhlal H.

PLoS One. 2014 Jun 13;9(6):e99601. doi: 10.1371/journal.pone.0099601. eCollection 2014.

19.

Up-regulation of the ATP-binding cassette transporter A1 inhibits hepatitis C virus infection.

Bocchetta S, Maillard P, Yamamoto M, Gondeau C, Douam F, Lebreton S, Lagaye S, Pol S, Helle F, Plengpanich W, Guérin M, Bourgine M, Michel ML, Lavillette D, Roingeard P, le Goff W, Budkowska A.

PLoS One. 2014 Mar 19;9(3):e92140. doi: 10.1371/journal.pone.0092140. eCollection 2014.

20.

Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry.

Douam F, Dao Thi VL, Maurin G, Fresquet J, Mompelat D, Zeisel MB, Baumert TF, Cosset FL, Lavillette D.

Hepatology. 2014 Mar;59(3):776-88. doi: 10.1002/hep.26733. Epub 2014 Jan 28.

PMID:
24038151
21.

Virus-like particle vaccine induces cross-protection against human metapneumovirus infections in mice.

Lévy C, Aerts L, Hamelin MÈ, Granier C, Szécsi J, Lavillette D, Boivin G, Cosset FL.

Vaccine. 2013 Jun 7;31(25):2778-85. doi: 10.1016/j.vaccine.2013.03.051. Epub 2013 Apr 11.

PMID:
23583815
22.

The antimalarial ferroquine is an inhibitor of hepatitis C virus.

Vausselin T, Calland N, Belouzard S, Descamps V, Douam F, Helle F, François C, Lavillette D, Duverlie G, Wahid A, Fénéant L, Cocquerel L, Guérardel Y, Wychowski C, Biot C, Dubuisson J.

Hepatology. 2013 Jul;58(1):86-97. doi: 10.1002/hep.26273. Epub 2013 May 14.

PMID:
23348596
23.

Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps.

Dao Thi VL, Granier C, Zeisel MB, Guérin M, Mancip J, Granio O, Penin F, Lavillette D, Bartenschlager R, Baumert TF, Cosset FL, Dreux M.

J Biol Chem. 2012 Sep 7;287(37):31242-57. doi: 10.1074/jbc.M112.365924. Epub 2012 Jul 5.

24.

Matrigel-embedded 3D culture of Huh-7 cells as a hepatocyte-like polarized system to study hepatitis C virus cycle.

Molina-Jimenez F, Benedicto I, Dao Thi VL, Gondar V, Lavillette D, Marin JJ, Briz O, Moreno-Otero R, Aldabe R, Baumert TF, Cosset FL, Lopez-Cabrera M, Majano PL.

Virology. 2012 Mar 30;425(1):31-9. doi: 10.1016/j.virol.2011.12.021. Epub 2012 Jan 24.

25.

Distinct roles in folding, CD81 receptor binding and viral entry for conserved histidine residues of hepatitis C virus glycoprotein E1 and E2.

Boo I, teWierik K, Douam F, Lavillette D, Poumbourios P, Drummer HE.

Biochem J. 2012 Apr 1;443(1):85-94. doi: 10.1042/BJ20110868.

PMID:
22240035
26.

A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques.

Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J, Cangialosi A, Du Chéné I, LeGrand R, Mangeot I, Lavillette D, Bellier B, Cosset FL, Tangy F, Klatzmann D, Dalba C.

Sci Transl Med. 2011 Aug 3;3(94):94ra71. doi: 10.1126/scitranslmed.3002330.

27.

Identification of interactions in the E1E2 heterodimer of hepatitis C virus important for cell entry.

Maurin G, Fresquet J, Granio O, Wychowski C, Cosset FL, Lavillette D.

J Biol Chem. 2011 Jul 8;286(27):23865-76. doi: 10.1074/jbc.M110.213942. Epub 2011 May 9.

28.

EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.

Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoël M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF.

Nat Med. 2011 May;17(5):589-95. doi: 10.1038/nm.2341. Epub 2011 Apr 24.

29.

Cell entry of enveloped viruses.

Cosset FL, Lavillette D.

Adv Genet. 2011;73:121-83. doi: 10.1016/B978-0-12-380860-8.00004-5. Review.

PMID:
21310296
30.

Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol.

Teissier E, Zandomeneghi G, Loquet A, Lavillette D, Lavergne JP, Montserret R, Cosset FL, Böckmann A, Meier BH, Penin F, Pécheur EI.

PLoS One. 2011 Jan 25;6(1):e15874. doi: 10.1371/journal.pone.0015874.

31.

Characterization of hepatitis C virus pseudoparticles by cryo-transmission electron microscopy using functionalized magnetic nanobeads.

Bonnafous P, Perrault M, Le Bihan O, Bartosch B, Lavillette D, Penin F, Lambert O, Pécheur EI.

J Gen Virol. 2010 Aug;91(Pt 8):1919-30. doi: 10.1099/vir.0.021071-0. Epub 2010 Apr 7.

PMID:
20375221
32.

HCV research 20 years after discovery: a summary of the 16th international symposium on hepatitis C virus and related viruses.

Pawlotsky JM, Cocquerel L, Durantel D, Lavillette D, Lerat H, Pécheur EI, Polyak SJ, Tautz N, Thimme R.

Gastroenterology. 2010 Jan;138(1):6-12.e1-2. doi: 10.1053/j.gastro.2009.11.018. Epub 2009 Nov 18. No abstract available.

PMID:
19931267
33.

Fusogenic membrane glycoproteins induce syncytia formation and death in vitro and in vivo: a potential therapy agent for lung cancer.

Lin EH, Salon C, Brambilla E, Lavillette D, Szecsi J, Cosset FL, Coll JL.

Cancer Gene Ther. 2010 Apr;17(4):256-65. doi: 10.1038/cgt.2009.74. Epub 2009 Nov 6.

PMID:
19893593
34.

Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening.

Trotard M, Lepère-Douard C, Régeard M, Piquet-Pellorce C, Lavillette D, Cosset FL, Gripon P, Le Seyec J.

FASEB J. 2009 Nov;23(11):3780-9. doi: 10.1096/fj.09-131920. Epub 2009 Jul 16.

PMID:
19608626
35.

The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection.

Benedicto I, Molina-Jiménez F, Bartosch B, Cosset FL, Lavillette D, Prieto J, Moreno-Otero R, Valenzuela-Fernández A, Aldabe R, López-Cabrera M, Majano PL.

J Virol. 2009 Aug;83(16):8012-20. doi: 10.1128/JVI.00038-09. Epub 2009 Jun 10.

36.

Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains.

Dreux M, Dao Thi VL, Fresquet J, Guérin M, Julia Z, Verney G, Durantel D, Zoulim F, Lavillette D, Cosset FL, Bartosch B.

PLoS Pathog. 2009 Feb;5(2):e1000310. doi: 10.1371/journal.ppat.1000310. Epub 2009 Feb 20.

37.

Contribution of redox status to hepatitis C virus E2 envelope protein function and antigenicity.

Fenouillet E, Lavillette D, Loureiro S, Krashias G, Maurin G, Cosset FL, Jones IM, Barbouche R.

J Biol Chem. 2008 Sep 26;283(39):26340-8. doi: 10.1074/jbc.M805221200. Epub 2008 Jul 30.

38.

The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus.

Meertens L, Bertaux C, Cukierman L, Cormier E, Lavillette D, Cosset FL, Dragic T.

J Virol. 2008 Apr;82(7):3555-60. doi: 10.1128/JVI.01977-07. Epub 2008 Jan 30.

39.

The exchangeable apolipoprotein ApoC-I promotes membrane fusion of hepatitis C virus.

Dreux M, Boson B, Ricard-Blum S, Molle J, Lavillette D, Bartosch B, Pécheur EI, Cosset FL.

J Biol Chem. 2007 Nov 2;282(44):32357-69. Epub 2007 Aug 30.

40.

Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus.

Lavillette D, Pécheur EI, Donot P, Fresquet J, Molle J, Corbau R, Dreux M, Penin F, Cosset FL.

J Virol. 2007 Aug;81(16):8752-65. Epub 2007 May 30.

41.

Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol.

Pécheur EI, Lavillette D, Alcaras F, Molle J, Boriskin YS, Roberts M, Cosset FL, Polyak SJ.

Biochemistry. 2007 May 22;46(20):6050-9. Epub 2007 Apr 25.

42.

High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.

Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, Keck Z, Foung S, Vu-Dac N, Dubuisson J, Bartenschlager R, Lavillette D, Cosset FL.

J Biol Chem. 2006 Jul 7;281(27):18285-95. Epub 2006 May 4.

43.

Significant redox insensitivity of the functions of the SARS-CoV spike glycoprotein: comparison with HIV envelope.

Lavillette D, Barbouche R, Yao Y, Boson B, Cosset FL, Jones IM, Fenouillet E.

J Biol Chem. 2006 Apr 7;281(14):9200-4. Epub 2006 Jan 17.

44.

Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes.

Lavillette D, Bartosch B, Nourrisson D, Verney G, Cosset FL, Penin F, Pécheur EI.

J Biol Chem. 2006 Feb 17;281(7):3909-17. Epub 2005 Dec 15.

45.

Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee.

Youn JW, Park SH, Lavillette D, Cosset FL, Yang SH, Lee CG, Jin HT, Kim CM, Shata MT, Lee DH, Pfahler W, Prince AM, Sung YC.

Hepatology. 2005 Dec;42(6):1429-36.

PMID:
16317673
46.

Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B, Cosset FL, Ball JK, Patel AH.

J Virol. 2005 Sep;79(17):11095-104.

48.

Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection.

Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E, Sakellariou G, Intrator L, Bartosch B, Pawlotsky JM, Cosset FL.

J Virol. 2005 May;79(10):6023-34.

49.

Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus.

Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, Bain C, Patel AH, Dubuisson J, Ball JK, Cosset FL.

Hepatology. 2005 Feb;41(2):265-74.

PMID:
15660396

Supplemental Content

Loading ...
Support Center